Loading quotes...
Forecast
The analysts' average price target is €42.85 (+39.12%). The median is €42.85 (+39.12%).
| Buy |
4 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 300.54M | 17.30% |
| Gross profit | 257.61M | 21.45% |
| Net profit | 106.9M | 599.98% |
| EBITDA | 144.57M | 107.81% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.87B |
Number of shares | 124.77M |
52-week high/low | €38.22 - €21.45 |
| Dividends | No |
Next dividend | €7.25 |
Beta | 1.11 |
P/E ratio | 12.25 |
PEG ratio | 0.07 |
P/B ratio | -20.97 |
P/S ratio | 3.26 |
Company profile
| Name | INDIVIOR PHARMACEUTICALS INC NPV |
| CEO | Joseph J. Ciaffoni |
| Employees | 833 |
